- Record: found
- Abstract: found
- Article: found
Bopindolol for the Treatment of Chronic Stable Angina pectoris - A Clinical Study of the Relationship between Dose and Effect
D. Holmes a , Z. Fryda-Kaurimsky† a , K. Krueger b
12 November 2008
Stable angina pectoris, Exercise testing, Beta-blockade, Bopindolol
Abstract
Following a 4-week placebo period, 19 patients (12 male, average age 62.3 years) with chronic stable angina pectoris and a positive exercise test were treated with the beta-adrenoceptor antagonist bopindolol at increasing doses of 0.5, 1 and 2 mg, each being given once daily for 4 weeks. For the final 4 weeks of the study, active treatment was replaced by placebo. Maximum tolerated exercise (bicycle ergometry, performed 24 h after drug administration) increased dose-dependently from 519 ± 59 s (baseline) to 758 ± 95s with 2 mg (p < 0.001) and fell again to 508 ± 48 s (placebo). The frequency of anginal attacks also fell dose-dependently from an average of 5.4 per week (baseline) to 0.5 with 2 mg (p < 0.001) and rose again to 5.1 per week when active treatment was stopped.
Related collections
Author and article information
Journal
Affiliations
Article
174638 Cardiology 1990;77:459–465Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.